Neurizon Therapeutics has received ethics approval for an Australia-based Phase 1 clinical trial that will test an oral liquid formulation of NUZ-001, which the company is developing for amyotrophic lateral sclerosis (ALS), in healthy volunteers. A tablet version of NUZ-001 is being tested in a Phase 2/3 clinical…
Inflammation may explain why ALS progression is faster for some
Today is my late husband’s 66th birthday. ALS took Jeff from our family just five days after he turned 60, and only 19 months after his diagnosis. Hearing the words, “This is ALS,” in the fall of 2018 was shocking and unbelievable. The early weeks and months after his…
An international team of scientists has developed an RNA-based experimental medicine that has the potential to reduce clumping of the TDP-43 protein, a key molecular feature of amyotrophic lateral sclerosis (ALS). The researchers determined, in precise molecular detail, how the RNA-based therapy interacts with the TDP-43 protein and showed…
In a recent episode of the “Hidden Brain” podcast, behavioral scientist Dave Evans discussed radical acceptance. He described his 69-year-old wife, Claudia, receiving a terminal cancer diagnosis and how they chose to skip the denial, anger, and depression that often come with grief. They moved straight to acceptance, allowing…
by Lindsey Beard
Families Are Waiting. I Know Because Mine Did.
When my father, Mickey, was diagnosed with amyotrophic lateral sclerosis (ALS), I was a sophomore in high school. Our world changed overnight. Like so many families, we were suddenly navigating a disease we barely understood — one that moves quickly and gives you very little time to adjust. We…
Dutch Bros is holding its annual Drink One for Dane Day of Giving fundraiser this Friday, May 15, with the Dutch Bros Foundation and franchisees donating $1 from every drink sold to support the fight against amyotrophic lateral sclerosis (ALS). The event raises funds and awareness of…
I spent five days last week corresponding with a fellow ALS patient in the U.K. We met during a unique online event that reminded me that, while this disease can feel isolating, the ALS community wraps all the way around the globe. Beyond the connection, I walked away with…
COYA 302, Coya Therapeutics’ investigational therapy for amyotrophic lateral sclerosis (ALS) — shown in an early clinical trial to slow disease progression in a small number of patients — has been awarded fast track status by the U.S. Food and Drug Administration (FDA). That designation is intended to…
The ALS Association has awarded $3 million to help expand access to specialized amyotrophic lateral sclerosis (ALS) care in underserved and geographically isolated communities across the U.S. The funding comes from the organization’s Hoffman ALS Clinic Development and Capacity Awards programs, established through a historic $58 million…
Recent Posts
- Inflammation may explain why ALS progression is faster for some
- Neurizon gets OK to test liquid form of ALS medication in Australia
- On his birthday, I remember the person who taught me to live fully
- RNA therapy shows promise for addressing key driver of ALS
- Practicing radical acceptance is difficult for me in life with ALS